当前位置: 首页 >> 检索结果
1. Factors associated with interstitial lung disease among patients with idiopathic inflammatory myopathies.
作者: Jesse C Wilkerson.;Frederick W Miller.;Matthew F Bridge.;Gary J Larson.;Shepherd H Schurman.;Stavros Garantziotis.;Payam N Farhadi.;Adam Schiffenbauer.;Lisa G Rider.
来源: Rheumatology (Oxford). 2026年65卷3期
Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders that often affect the lungs as IIM-associated interstitial lung disease (IIM-ILD). We used Meta-ANalysis of Transethnic Associations (MANTRA) and machine learning methods to evaluate predictors of IIM-ILD.
2. Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis.
作者: Abderrahmane Elhannani.;Marie-Elise Martel.;Aurore Collet.;Aurélien Chepy.;Sébastien Sanges.;Éric Hachulla.;Sylvain Dubucquoi.;David Launay.;Vincent Sobanski.
来源: Rheumatology (Oxford). 2025年64卷12期6023-6035页
Anti-RNA polymerase III antibodies (ARA) are frequent in systemic sclerosis (SSc). However, the reported prevalence is variable among studies and some clinical associations are debated. We aimed (i) to update the recent data on overall ARA prevalence in SSc and heterogeneity between centres; and (ii) to describe their clinical associations.
3. A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis.
作者: Elie Naddaf.;Michael P Skolka.;Larry Prokop.;Mazen M Dimachkie.;Jean-Yves Hogrel.;Olivier Benveniste.;Zhen Wang.;Jay Mandrekar.;Colin P West.;M Hassan Murad.
来源: Rheumatology (Oxford). 2025年64卷7期4125-4132页
IBM is characterized by slowly progressive muscle weakness making it challenging to detect significant changes in weakness during a clinical trial. Trial participants receiving placebo may behave differently from in natural history studies. We aimed to quantify the change in muscle strength and IBM Functional Rating Scale (IBMFRS) of IBM patients receiving placebo during clinical trials.
4. Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis.
作者: Anna Pathak.;Eoin M Kelleher.;Isabelle Brennan.;Raj Amarnani.;Amanda Wall.;Robert Murphy.;Hopin Lee.;Beth Fordham.;Anushka Irani.
来源: Rheumatology (Oxford). 2025年64卷8期4495-4516页
Sleep disturbance is a key symptom of fibromyalgia and a risk factor for chronic widespread pain. This systematic review and meta-analysis aims to assess the effectiveness of pharmacological treatments and cognitive behavioural therapy (CBT) in improving sleep quality in fibromyalgia patients.
5. Abatacept and the risk of malignancy: a meta-analysis across disease indications.
作者: Benjamin P Zuckerman.;Mark Gibson.;Ritika Roy.;Mark Hughes.;Daksh Mehta.;Zijing Yang.;Maryam Adas.;Kenrick Ng.;Mark D Russell.;Andrew Cope.;Sam Norton.;James Galloway.
来源: Rheumatology (Oxford). 2025年64卷6期3280-3287页
To estimate the association between abatacept use and the incidence of malignancy excluding non-melanomatous skin cancers (NMSCs).
6. Imaging tests as predictors of progression to rheumatoid arthritis in clinically suspect arthralgia: a systematic review and meta-analysis.
To determine and compare the diagnostic accuracy of imaging tests for the prediction of RA progression in people with inflammatory joint pain or clinically suspect arthralgia (CSA).
7. Association between antiphospholipid antibodies and diffuse alveolar haemorrhage risk in systemic lupus erythematosus: a systematic review and meta-analysis.
作者: Mariana González-Treviño.;Gabriel Figueroa-Parra.;Jeffrey X Yang.;Larry J Prokop.;Sherif M Gamal.;Mercedes A García.;Judith A James.;Jason S Knight.;M Hassan Murad.;Javier Narvaez.;Bernardo A Pons-Estel.;Rosana M Quintana.;Ulrich Specks.;Xuwei Yang.;Alí Duarte-García.
来源: Rheumatology (Oxford). 2025年64卷4期1598-1608页
To assess the association of aPL and diffuse alveolar haemorrhage (DAH) in patients with SLE by performing a systematic review and meta-analysis.
8. Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-wide meta-analysis and Mendelian randomization.
作者: Sizheng Steven Zhao.;Sarah L Mackie.;Susanna C Larsson.;Stephen Burgess.;Shuai Yuan.
来源: Rheumatology (Oxford). 2025年64卷5期3012-3018页
PMR is an age-related inflammatory disease of unknown cause. We aimed to identify potentially modifiable risk factors and therapeutic targets for preventing or treating PMR.
9. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
作者: Eline J Arends.;Mihaela Zlei.;Christopher M Tipton.;Jasna Cotic.;Zgjim Osmani.;Fenna J de Bie.;Sylvia W A Kamerling.;Andre van Maurik.;Richard Dimelow.;Yun Irene Gregan.;Norma Lynn Fox.;Ton J Rabelink.;David A Roth.;Ignacio Sanz.;Jacques J M van Dongen.;Cees van Kooten.;Y K Onno Teng.
来源: Rheumatology (Oxford). 2024年63卷9期2387-2398页
Autoreactive memory B cells (MBCs) contribute to chronic and progressive courses in autoimmune diseases like SLE. The efficacy of belimumab (BEL), the first approved biologic treatment for SLE and LN, is generally attributed to depletion of activated naïve B cells and inhibition of B-cell activation. BEL's effect on MBCs is currently unexplained. We performed an in-depth cellular and transcriptomic analysis of BEL's impact on the blood MBC compartment in patients with SLE.
10. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study.
作者: Gonzalo Borrego-Yaniz.;Lourdes Ortiz-Fernández.;Adela Madrid-Paredes.;Martin Kerick.;José Hernández-Rodríguez.;Sarah L Mackie.;Augusto Vaglio.;Santos Castañeda.;Roser Solans.;Jaume Mestre-Torres.;Nader Khalidi.;Carol A Langford.;Steven Ytterberg.;Lorenzo Beretta.;Marcello Govoni.;Giacomo Emmi.;Marco A Cimmino.;Torsten Witte.;Thomas Neumann.;Julia Holle.;Verena Schönau.;Gregory Pugnet.;Thomas Papo.;Julien Haroche.;Alfred Mahr.;Luc Mouthon.;Øyvind Molberg.;Andreas P Diamantopoulos.;Alexandre Voskuyl.;Thomas Daikeler.;Christoph T Berger.;Eamonn S Molloy.;Daniel Blockmans.;Yannick van Sleen.;Mark Iles.;Louise Sorensen.;Raashid Luqmani.;Gary Reynolds.;Marwan Bukhari.;Shweta Bhagat.;Norberto Ortego-Centeno.;Elisabeth Brouwer.;Peter Lamprecht.;Sebastian Klapa.;Carlo Salvarani.;Peter A Merkel.;María C Cid.;Miguel A González-Gay.;Ann W Morgan.;Javier Martin.;Ana Márquez.; .; .; .
来源: Lancet Rheumatol. 2024年6卷6期e374-e383页
Giant cell arteritis is an age-related vasculitis that mainly affects the aorta and its branches in individuals aged 50 years and older. Current options for diagnosis and treatment are scarce, highlighting the need to better understand its underlying pathogenesis. Genome-wide association studies (GWAS) have emerged as a powerful tool for unravelling the pathogenic mechanisms involved in complex diseases. We aimed to characterise the genetic basis of giant cell arteritis by performing the largest GWAS of this vasculitis to date and to assess the functional consequences and clinical implications of identified risk loci.
11. Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis.
作者: Ivet Etchegaray-Morales.;Claudia Mendoza-Pinto.;Pamela Munguía-Realpozo.;Juan Carlos Solis-Poblano.;Socorro Méndez-Martínez.;Jorge Ayón-Aguilar.;Carlos Abud-Mendoza.;Mario García-Carrasco.;Ricard Cervera.
来源: Rheumatology (Oxford). 2024年63卷8期2047-2055页
To investigate the risk of DM and evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE.
12. Pharmacological interventions for early-stage frozen shoulder: a systematic review and network meta-analysis.
作者: Juan Enrique Berner.;Marios Nicolaides.;Stephen Ali.;Georgios Pafitanis.;Jane Preece.;Sally Hopewell.;Jagdeep Nanchahal.
来源: Rheumatology (Oxford). 2024年63卷12期3221-3233页
To evaluate the efficacy of pharmacological interventions for treating early-stage, pain predominant, adhesive capsulitis, also known as frozen shoulder.
13. The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis.
作者: Stephanie Lembke.;Gary J Macfarlane.;Gareth T Jones.
来源: Rheumatology (Oxford). 2024年63卷12期3211-3220页
Previous attempts to pool prevalence studies in PsA have failed to take account of important methodological differences between studies that may have created biased estimates. The aim of this review is to estimate the prevalence of PsA within the adult general population worldwide, considering potential differences between population-based and health administrative studies separately.
14. Identification of the VLDLR locus associated with giant cell arteritis and the possible causal role of low-density lipoprotein cholesterol in its pathogenesis.
作者: Takeshi Iwasaki.;Ryu Watanabe.;Hui Zhang.;Motomu Hashimoto.;Akio Morinobu.;Fumihiko Matsuda.
来源: Rheumatology (Oxford). 2024年63卷10期2754-2762页
To elucidate the association between genetic variants and the risk of GCA via large-scale genome-wide association studies (GWAS). In addition, to assess the causal effect of a specific molecule by employing the obtained GWAS results as genetic epidemiological tools.
15. Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis.
作者: Melanie A Holden.;Miriam Hattle.;Jos Runhaar.;Richard D Riley.;Emma L Healey.;Jonathan Quicke.;Danielle A van der Windt.;Krysia Dziedzic.;Marienke van Middelkoop.;Danielle Burke.;Nadia Corp.;Amardeep Legha.;Sita Bierma-Zeinstra.;Nadine E Foster.; .; .
来源: Lancet Rheumatol. 2023年5卷7期e386-e400页
Many international clinical guidelines recommend therapeutic exercise as a core treatment for knee and hip osteoarthritis. We aimed to identify individual patient-level moderators of the effect of therapeutic exercise for reducing pain and improving physical function in people with knee osteoarthritis, hip osteoarthritis, or both.
16. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
作者: Philip J Mease.;Dafna D Gladman.;Joseph F Merola.;Peter Nash.;Stacy Grieve.;Victor Laliman-Khara.;Damon Willems.;Vanessa Taieb.;Adam R Prickett.;Laura C Coates.
来源: Rheumatology (Oxford). 2024年63卷7期1779-1789页
To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b/tsDMARDs) for PsA using network meta-analysis (NMA).
17. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
作者: Atul Deodhar.;Pedro M Machado.;Michael Mørup.;Vanessa Taieb.;Damon Willems.;Michelle Orme.;David Pritchett.;Lianne S Gensler.
来源: Rheumatology (Oxford). 2024年63卷5期1195-1205页
To compare the efficacy and safety of bimekizumab 160 mg every 4 weeks, a selective inhibitor of IL-17F and IL-17A, with those of biologic/targeted synthetic DMARDs (b/tsDMARDs) in non-radiographic axial SpA (nr-axSpA) and AS.
18. HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis.
作者: Stamatia Katelani.;George E Fragoulis.;Athanasios-Dimitrios Bakasis.;Abraham Pouliakis.;Elena Nikiphorou.;Fabiola Atzeni.;Theodoros Androutsakos.
来源: Rheumatology (Oxford). 2023年62卷SI3期SI252-SI259页
The objective of this study was to assess the possibility of HBV reactivation (HBVr) in patients with RA under anti-IL-6 treatment.
19. Neuropsychiatric lupus in late- and early-onset systemic lupus erythematosus patients: a systematic review and meta-analysis.
Late-onset SLE is usually milder and associated with lower frequency of LN and neuropsychiatric manifestations. The diagnosis of NPSLE is especially challenging in older patients because of increased incidence of neurological comorbidities. We performed a systematic review and meta-analysis to evaluate the differences in NPSLE manifestations in early-onset (<50-year-old) vs late-onset (≥50-year-old) SLE patients.
20. Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis.
作者: Fanni A Meznerics.;Lajos V Kemény.;Emese Gunther.;Eszter Bakó.;Fanni Dembrovszky.;Bence Szabó.;Anna Ascsillán.;Elmar Lutz.;Dezsö Csupor.;Péter Hegyi.;András Bánvölgyi.;György Nagy.
来源: Rheumatology (Oxford). 2023年62卷6期2048-2059页
The multibiomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in RA. Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA.
|